Targeting maladaptive reactivity to negative affect in emerging adults with cannabis use disorder: A preliminary test and proof of concept.

Citation metadata

Publisher: Elsevier Science Publishers
Document Type: Brief article
Length: 342 words

Document controls

Main content

Abstract :

Highlights * A treatment targeting reactivity to negative affect (AMT) was compared to CBT for cannabis use disorder (CUD). * AMT reduced negative affect and reactivity to negative affect more than CBT. * AMT resulted in somewhat greater reduction in quantity of cannabis use than CBT. Abstract Introduction Cannabis use disorder (CUD) is a growing public health concern, and is highly comorbid with negative affective conditions such as anxiety and depression. Late adolescence and early adulthood represents a time of rapid emotion regulation development, as well as the onset of anxiety, mood, and substance use disorders, especially CUD. Maladaptive cognitive, behavioral, and emotional responding to one's own negative affect (in an effort to eliminate it) is associated with substance use, and represents a novel treatment target to improve outcomes of treatment for substance misuse. Method: After development of a manual for a novel intervention, Affect Management Treatment (AMT) for CUD, a pilot randomized clinical trial was conducted in 18--25 year-old participants with CUD to evaluate the impact of this approach on negative affect, constructs (e.g., distress intolerance) representing maladaptive reactivity to negative affect, and cannabis use. Participants (N = 52) received either 12 sessions of standard cognitive behavioral therapy (CBT) for CUD or 12 sessions of AMT and were assessed on measures of negative affect, reactivity to negative affect, cannabis use, and cannabis use problems at baseline, throughout treatment, post-treatment, and 6-mo follow-up. Results: AMT outperformed CBT in reducing negative affect and reactivity to negative affect, and it had a significant impact on cannabis use and cannabis use problems. There were no statistically significant between-group differences on cannabis outcomes. Conclusions: AMT offers a novel, successful approach to the treatment of CUD. Author Affiliation: University of California, Los Angeles, USA * Corresponding author.UCLA Department of Psychiatry and Biobehavioral Sciences, Integrated Substance Abuse Programs, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA. Article History: Received 3 October 2021; Revised 27 December 2021; Accepted 5 January 2022 Byline: Kate Wolitzky-Taylor [kbtaylor@mednet.ucla.edu] (*), Suzette Glasner, Alexandra Tanner, Dara G. Ghahremani, Edythe D. London

Source Citation

Source Citation   

Gale Document Number: GALE|A692744302